SCHEMBL124411

SCHEMBL124411

CN(C)c1ccc(/C=C/C=C2\C(=O)NC(=S)N(c3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2=O)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.58
MEN1 O00255 4/20 0.58
PKM P14618 4/20 0.58
KMT2A Q03164 4/20 0.58
L3MBTL1 Q9Y468 4/20 0.58
ALDH1A1 P00352 3/20 0.58
MAPK1 P28482 3/20 0.58
NPSR1 Q6W5P4 3/20 0.58
PSMD14 O00487 2/20 0.58
THRB P10828 2/20 0.58
MMP2 P08253 1/20 0.58
PPARG P37231 1/20 0.58
NCOA2 Q15596 1/20 0.58
METAP1 P53582 2/20 0.55
BCL2A1 Q16548 2/20 0.50
APP P05067 9/20 0.46
SNCA P37840 6/20 0.46
TDP1 Q9NUW8 2/20 0.43
LMNA P02545 2/20 0.43
OPRK1 P41145 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL124459 0.79 ITGA4 (0.58) MAPTMEN1PKMKMT2AL3MBTL1
SCHEMBL13184661 0.74 MAPT (0.79) MAPTMEN1PKMKMT2AL3MBTL1
SCHEMBL29350119 0.73 MAPT (1.00) MAPTMEN1PKMKMT2AL3MBTL1
SCHEMBL13184630 0.73 MAPT (1.00) MAPTMEN1PKMKMT2AL3MBTL1
SCHEMBL13184632 0.73 MAPT (0.81) MAPTMEN1PKMKMT2AL3MBTL1
SCHEMBL8026269 0.72 METAP1 (1.00) MAPTMEN1PKMKMT2AL3MBTL1
SCHEMBL13184656 0.72 MAPT (0.79) MAPTMEN1PKMKMT2AL3MBTL1
SCHEMBL13184631 0.71 MAPT (0.78) MAPTMEN1PKMKMT2AL3MBTL1
SCHEMBL14713028 0.70 MAPT (0.67) MAPTMEN1PKMKMT2AL3MBTL1
SCHEMBL12218472 0.70 MAPT (0.61) MAPTMEN1PKMKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120059163-A1 Non-linear opticaly active molecules, their synthesis, and use OPTIMER PHOTONICS, INC. (US) 2012-03-08 US disclosed
US-20080004415-A1 Non-linear optically active molecules, their synthesis, and use OPTIMER PHOTONICS, INC. (US) 2008-01-03 US disclosed
US-20080004415-A1 Non-linear optically active molecules, their synthesis, and use OPTIMER PHOTONICS, INC. (US) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059163-A1 Non-linear opticaly active molecules, their synthesis, and use INCENP, CYBA, ADCY5 MAPT 2242/4885MEN1 4480/4885PKM 447/4885
US-20080004415-A1 Non-linear optically active molecules, their synthesis, and use INCENP, CYBA, PAICS MAPT 2173/4885MEN1 4473/4885PKM 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.